Email this article PREDICTORS OF FORMATION OF EARLY COMPLICATIONS IN PATIENTS WITH CHRONIC HEPATITIS B AND B WITH DELTA AGENT WITH RESULTS IN LIVER CIRRHOSIS
- Authors: Abdukadirova M.A1, Khikmatullaeva A.S1
-
Affiliations:
- Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan
- Issue: Vol 24, No 4 (2019)
- Pages: 193-198
- Section: Articles
- URL: https://bakhtiniada.ru/1560-9529/article/view/43092
- DOI: https://doi.org/10.18821/1560-9529-2019-24-4-193-198
- ID: 43092
Cite item
Full Text
Abstract
Liver cirrhosis (LC) should be considered as a severe, progressive disease with systemic manifestations. Early detection and elimination of risk factors for the development of LC complications are essential for improving the quality of life of patients. In order to study the clinical aspects of the initial stages of LC, we examined 207 patients with LC HBV and HDV etiology. The study of the characteristics of the initial manifestations of LC is necessary to identify predictors of the development of severe complications and prevent disability of patients.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
M. A Abdukadirova
Research Institute of Virology, Ministry of Health of the Republic of Uzbekistanдоктор мед. наук, ст. науч. сотр., руководитель гранта НИИ Вирусологии Минздрава Респуб-лики Узбекистан. Tashkent, Uzbekistan
A. S Khikmatullaeva
Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan
Email: aziza9999@rambler.ru
Doctor of Medical Sciences, Senior Researcher, Deputy Director for Research, Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan Tashkent, Uzbekistan
References
- Сторожаков Г.И., Мерзликина Н.Н., Федоров И.Г. Анализ летальности у больных циррозом печени. Российский медицинский журнал. 2009; 4: 10-4.
- Ивашкин В.Т., Ющук Н.Д., Климова Е.А., Маевская М.В., Хнойко О.О., Шестякова И.В. и др. Рекомендации по диагностике и лечению взрослых больных гепатитом С. М.; 2017.
- European Association for the study of the Liver (EASL). Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology 2011; 55: 245-64.
- European Association for the study of the Liver (EASL). Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. Journal of Hepatology, 2012; 57: 167-85.
- Ивашкин В.Т. Болезни печени и желчевыводящих путей. Руководство для врачей под ред. В.Т. Ивашкин. 2-е издание. М.: Издательский дом «М-Вести»; 2005.
- Минушин О.Н., Масловский Л.В., Фролова А.А. Цирроз печени: этиологические и прогностические аспекты. Фарматека. 2013; 14: 98 - 103.
- Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295: 65-73.
- Global Burden of Disease Study 2013 Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386: 743-800.
- Lee M-H, Yang H-I, Liu J, et al. R.E.V.E.A.L.-HBV Study Group: Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013; 58: 546-54.
- Li Y., Wang H., Li D., Hu J., Wang H. et al. Occult hepatitis B virus infection in Chinese cryptogenic intrahepatic cholangiocarcinoma patient population. J. Clin. Gastroenterology. 2014; 48(10): 878-82.
- Schweitzer A., Horn J., Mikolajczyk R.T., Krause G., Ott J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386: 1546-55.
Supplementary files
